A biosignature tool helps women avoid unnecessary radiotherapy after undergoing lumpectomy for ductal carcinoma in situ (DCIS) ― and also identifies women who need more intense treatment. The ...

March 23, 2011 — Long-term results from 2 large trials of ductal carcinoma in situ (DCIS) have shown that these women have an excellent prognosis and are more likely to die from other causes than from ...

Breast-conserving surgery plus radiation therapy (RT) could be a treatment option for selected patients with extensive, pure ductal carcinoma in situ (DCIS), according to a retrospective study. Among ...

Women with ductal carcinoma in situ -- DCIS -- who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. What’s controversial about DCIS is whether or not it should be considered ...

Mastectomy is done if the DCIS tumor is thought to be too large for lumpectomy. Mastectomy is also done if there is concern that the DCIS may involve other parts of the breast. In the U.S., about 75 ...

Sandie Walters’ breast cancer was diagnosed in 2007 during a routine screening mammogram, and soon after, the 58-year-old Grand Rapids, Mich., woman was sitting in a surgeon’s office. His ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Surgical management of ductal carcinoma in situ improved survival outcomes compared with non-operative ...

Adjuvant radiation therapy (RT) for good-risk ductal carcinoma in situ (DCIS) reduced long-term ipsilateral breast recurrence (IBR) by more than 50% compared with observation, results of a large ...

Those aren’t words you want to hear from your doctor, especially when he’s called to report the results of a biopsy. I scrambled to find a quiet corner and my head began to throb as I listened. Ductal ...

PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer. Background: A significant amount of ...

In women with ductal carcinoma in situ (DCIS) lumpectomy plus radiation was linked with a small clinical benefit in lowered risk of breast cancer death compared with lumpectomy or mastectomy alone, ...